Clinical Criteria for Subtyping Parkinson’s Disease: Differences in imaging and CSF biomarkers and longitudinal progression
Objective: To introduce a new practical classification method to assign individuals with Parkinson’s disease (PD) into distinct subtypes using baseline dataset, then to compare neuroimaging,…Relationship between non-motor symptoms and dopamine transporter activity in Parkinson’ s disease
Objective: We investigated whether dopamine transporter single-photon emission computed tomography (DAT-SPECT) binding correlates to non-motor symptoms in patients with Parkinson’s disease (PD). Background: DAT-SPECT binding…99mTc-TRODAT-1 SPECT imaging in early and late onset Parkinson’s disease.
Objective: In this study we tried to determine the TRODAT SPECT findings in EOPD as compared to LOPD. Background: 99mTc-TRODAT-1, which binds to the dopamine…The combination of the MIBG myocardial scintigraphy and DATSPECT contributes to the diagnosis of PD and other related disorders.
Objective: To evaluate MIBG and DAT SPECT for the diagnosis of Parkinson’s disease (PD) and related disorders, we performed 123I-meta-iodobenzylguanzylguanidine (MIBG) myocardial scintigraphy and (123I)-FP-CIT…SPECT imaging of striatal DAT availability in Parkinson’s: changes over time and relevance to dyskinesias
Objective: This study was designed to explore in Parkinson’s disease (PD) the role of dopamine transporter (DAT)-specific single photon emission computed tomography (SPECT) imaging as a…DAT SPECT data of Parkinson’s disease patients with and without REM Sleep Pathology: A report from the DeNoPa cohort
Objective: To evaluate the DAT SPECT (Single photon emission computerized tomography of the dopamine transporter) parameters for Parkinson's disease (PD) patients with REM Sleep Behavior…Dynamic dopamine transporter images are helpful for diagnosing parkinsonism
Objective: This study is aimed at introducing a new method to get Dopamine transporter (DAT) imaging simultaneously with regional cerebral flow (CBF) imaging. Background: DAT…Nigrostriatal degeneration and serum BDNF levels in patients with “de novo” untreated Parkinson’s disease
Objective: To evaluate serum Brain-Derived NeurotrophicFactor(BDNF) levels in “de novo” untreated Parkinson's disease (PD) patients and their relationship to nigrostriatal degeneration measured with [123I]FP-CIT SPECT.…Levodopa induced dyskinesia and nicotinergic α4β2 acetylcholin receptor density: A multi-tracer imaging study
Objective: We investigated α4β2 acetylcholin receptor (nAChR) density in subjects with Parkinson's disease (PD) with and without levodopa-induced dyskinesia (LID) and its correlation with dopaminergic…Visual vs. automated analysis of [123I]FP-CIT SPECT scans in patients with parkinsonism
Objective: To investigate the differences between visual and automated analyses of brain dopamine transporter (DAT) SPECT scans. Background: Clinical evaluation of DAT SPECT scans typically…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.